Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-15-001378
Filing Date
2015-08-04
Accepted
2015-08-04 17:01:37
Documents
11
Period of Report
2015-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q nvls-20150630x10q.htm 10-Q 1410748
2 EX-10.1 nvls-20150630ex1019a0e04.htm EX-10.1 57721
3 EX-31.1 nvls-20150630ex311dfce47.htm EX-31.1 17083
4 EX-31.2 nvls-20150630ex312a18051.htm EX-31.2 17089
5 EX-32.1 nvls-20150630ex32132c058.htm EX-32.1 8748
  Complete submission text file 0001558370-15-001378.txt   3182757

Data Files

Seq Description Document Type Size
6 EX-101.INS nvls-20150630.xml EX-101.INS 342241
7 EX-101.SCH nvls-20150630.xsd EX-101.SCH 19046
8 EX-101.CAL nvls-20150630_cal.xml EX-101.CAL 23374
9 EX-101.DEF nvls-20150630_def.xml EX-101.DEF 60357
10 EX-101.LAB nvls-20150630_lab.xml EX-101.LAB 200953
11 EX-101.PRE nvls-20150630_pre.xml EX-101.PRE 142548
Mailing Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301
Business Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301 720-945-7700
Nivalis Therapeutics, Inc. (Filer) CIK: 0001626199 (see all company filings)

EIN.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37449 | Film No.: 151026345
SIC: 2834 Pharmaceutical Preparations